GHS1128
Hematoxylin Solution, Gill No. 1
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
form
solution
Quality Level
shelf life
Expiry date on the label.
IVD
for in vitro diagnostic use
concentration
2 g/L
pH
2.5-3.5
application(s)
hematology
histology
storage temp.
room temp
SMILES string
Oc1cc2C[C@@]3(O)COc4c(O)c(O)ccc4[C@H]3c2cc1O
InChI
1S/C16H14O6/c17-10-2-1-8-13-9-4-12(19)11(18)3-7(9)5-16(13,21)6-22-15(8)14(10)20/h1-4,13,17-21H,5-6H2/t13-,16+/m0/s1
InChI key
WZUVPPKBWHMQCE-XJKSGUPXSA-N
Application
Gill No. 1 formulation is used as a progressive cytology stain. Used with hematoxylin and eosin staining.
Other Notes
2 g/L certified hematoxylin
Still not finding the right product?
Explore all of our products under Hematoxylin Solution, Gill No. 1
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - STOT RE 2 Oral
target_organs
Kidney
Storage Class
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Michael J Turner et al.
Journal of neuroimmunology, 285, 4-12 (2015-07-23)
Alemtuzumab, a monoclonal antibody directed against human CD52, is used in the treatment of MS. To characterize the impact of anti-CD52 administration, a monoclonal antibody to mouse CD52 (anti-muCD52) was generated and evaluated in EAE mouse models of MS. A
Hideki Ishii et al.
Bioorganic & medicinal chemistry letters, 22(3), 1469-1474 (2012-01-17)
SAR studies for the exploration a novel class of anti-human immunodeficiency virus type 1 (HIV-1) agents based on the hematoxylin structure (1) are described. The systematic deoxygenations of 1 including asymmetric synthesis were conducted to obtain a compound showing high
Eleni Maniati et al.
Cell reports, 30(2), 525-540 (2020-01-16)
Although there are many prospective targets in the tumor microenvironment (TME) of high-grade serous ovarian cancer (HGSOC), pre-clinical testing is challenging, especially as there is limited information on the murine TME. Here, we characterize the TME of six orthotopic, transplantable syngeneic